Catalent Inc. will buy privately held Paragon Bioservices Inc. for $1.2 billion in cash, bolstering the contract drugmaker’s capabilities to make gene therapy drugs for biotech clients.
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
In seeking innovative players that could change pharma and healthcare, Med Ad News found the developer of an app that helps people determine what illnesses are in their neighborhoods; the creator of a wearable injector that allows patients on biologics to receive these drugs outside the clinic; and a designer of a deep learning network aimed at giving pharma and healthcare companies a handle on their data.
The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.
Bristol-Myers Squibb’s shareholders voted to approve the drugmaker’s $74 billion takeover of Celgene despite a campaign by activist hedge fund Starboard Value LP to scuttle the deal.
Novo Nordisk and Gilead Sciences will join forces on a clinical trial combining drugs from the two pharmaceutical firms to treat a progressive fatty liver disease known as NASH.
The loss of patent protection on two drugs is forcing Gilead Sciences to terminate about 20 percent of the company’s sales team, according to reports.
Asklepios BioPharmaceutical (AskBio) secured a $235 million investment from Vida Ventures and TPG Capital.
Fresenius Kabi is investing $100 million in expanding the German company’s manufacturing campus in Wilson County, North Carolina, which will add at least 445 new jobs.
U.S. authorities said 24 defendants were charged in connection with one of the largest healthcare fraud schemes prosecuted by the federal government, involving telemedicine companies and resulting in more than $1.2 billion of losses.
Regeneron Pharmaceuticals is investing $800 million in Alnylam Pharmaceuticals to develop treatments for eye and central nervous system diseases using gene-silencing RNA interference technology.
Shares of Merrimack Pharmaceuticals sunk after the company announced the discontinued development of an experimental solid tumor treatment and will lay off some employees.